Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more
Nyxoah (NYXH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.402x
Based on the latest financial reports, Nyxoah (NYXH) has a cash flow conversion efficiency ratio of -0.402x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.48 Million) by net assets ($50.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nyxoah - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nyxoah's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nyxoah Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyxoah ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AS HARJU ELEKTER EO 063
F:HD8
|
N/A |
|
Ether Capital Corporation
PINK:DTSRF
|
0.045x |
|
Marti Technologies Inc.
NYSE:MRT
|
0.034x |
|
Anson Resources Limited
OTCQB:ANSNF
|
-0.046x |
|
BINHO
IS:BINHO
|
-0.011x |
|
Senao International Co Ltd
TW:2450
|
0.135x |
|
Cemas Dokum Sanayi AS
IS:CEMAS
|
-0.024x |
|
Baoye Group Company Limited
F:BKG
|
0.006x |
Annual Cash Flow Conversion Efficiency for Nyxoah (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nyxoah from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $113.25 Million | $-49.23 Million | -0.435x | +4.85% |
| 2023-12-31 | $98.02 Million | $-44.78 Million | -0.457x | -91.15% |
| 2022-12-31 | $120.32 Million | $-28.76 Million | -0.239x | -40.19% |
| 2021-12-31 | $148.62 Million | $-25.34 Million | -0.170x | -195.34% |
| 2020-12-31 | $118.92 Million | $-6.86 Million | -0.058x | +97.42% |
| 2019-12-31 | $2.65 Million | $-5.93 Million | -2.238x | -187.50% |
| 2018-12-31 | $10.45 Million | $-8.14 Million | -0.779x | +57.47% |
| 2017-12-31 | $4.53 Million | $-8.29 Million | -1.831x | -- |